Conservative Nonsurgical Management of Spina Bifida

被引：4
作者：
Michael C. Carr
机构：
[1] Children’s Hospital of Philadelphia,Division of Urology
来源：
Current Urology Reports | 2010年 / 11卷 / 2期
关键词：
Spina bifida; Neuromodulation; Pharmacologic bladder management;
D O I：
10.1007/s11934-010-0096-6
中图分类号：
学科分类号：
摘要：
The nonsurgical management of patients with spina bifida is predicated on maintaining a compliant bladder of adequate size or correcting detrusor sphincter dyssynergy that can lead to progressive bladder damage and ultimately upper tract changes. Pharmacologic management, targeted at the detrusor and/or external sphincter, can be done. Neuromodulation using transcutaneous approaches with interferential electrostimulation, sacral (S2–S3) via digital transcutaneous electrical nerve stimulation, and percutaneous tibial nerve stimulation all have shown varied successes.
引用
收藏
页码：109 / 113
页数：4
相关论文
共 56 条
[1]  
Nanigian D(2008)Development and validation of the fecal incontinence and constipation quality of life measure in children with spina bifida J Urol 180 1770-1773
[2]  
Nguyen T(2007)Achieving fecal continence in patients with spina bifida: a descriptive cohort study J Urol 178 2640-2644
[3]  
Tanaka S(2009)Treatment of fecal incontinence with a comprehensive bowel management program J Pediatr Surg 44 1278-1283
[4]  
Vande Velde S(2008)Tap water irrigation and additives to optimize success with the Malone antegrade continence enema: the Indiana University algorithm J Urol 180 1757-1760
[5]  
Van Biervliet S(2009)Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review J Pediatr Urol 5 156-164
[6]  
Van Renterghem K(2009)Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance Arch Phys Med Rehabil 90 832-836
[7]  
Bischoff A(2008)The neurogenic bladder: medical management Pediatr Nephrol 23 717-725
[8]  
Levitt MA(2009)Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity J Urol 182 1548-1554
[9]  
Bauer C(2003)Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects Mayo Clinic Proc 78 696-331
[10]  
Bani-Hani A(1997)Complications of intravesical oxybutynin chloride in the pediatric myelomeningocele population J Urol 157 638-415
123456